Allogene Therapeutics, Inc. financial data

Symbol
ALLO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
210 East Grand Avenue, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.07K % +5.43%
Debt-to-equity 27.3 % +9.94%
Return On Equity -55.3 % +2.52%
Return On Assets -43.5 % +4.42%
Operating Margin -1.24M % -260%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 217M shares +28.5%
Common Stock, Shares, Outstanding 212M shares +25.8%
Entity Public Float 354M USD -36.4%
Common Stock, Value, Issued 212K USD +25.4%
Weighted Average Number of Shares Outstanding, Basic 195M shares +24.1%
Weighted Average Number of Shares Outstanding, Diluted 195M shares +24.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 22K USD -76.8%
Research and Development Expense 192M USD -20.8%
General and Administrative Expense 65.2M USD -9.02%
Operating Income (Loss) -273M USD +16.6%
Nonoperating Income (Expense) 16.1M USD +3301%
Net Income (Loss) Attributable to Parent -258M USD +21.3%
Earnings Per Share, Basic -1.32 USD/shares +36.8%
Earnings Per Share, Diluted -1.32 USD/shares +36.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 75.2M USD -9.55%
Cash, Cash Equivalents, and Short-term Investments 373M USD -16.8%
Assets, Current 303M USD -33.9%
Property, Plant and Equipment, Net 86.1M USD -13.5%
Operating Lease, Right-of-Use Asset 45.2M USD -29%
Other Assets, Noncurrent 2.33M USD -64.8%
Assets 549M USD -14.6%
Accounts Payable, Current 5.39M USD -8.53%
Employee-related Liabilities, Current 12.1M USD -4.1%
Contract with Customer, Liability, Current 86K USD 0%
Liabilities, Current 35.5M USD -4.2%
Operating Lease, Liability, Noncurrent 83.2M USD -5.77%
Other Liabilities, Noncurrent 7.76M USD +49.9%
Liabilities 127M USD -3.12%
Accumulated Other Comprehensive Income (Loss), Net of Tax -89K USD +90.7%
Retained Earnings (Accumulated Deficit) -1.82B USD -16.5%
Stockholders' Equity Attributable to Parent 422M USD -17.6%
Liabilities and Equity 549M USD -14.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -55.9M USD +16.1%
Net Cash Provided by (Used in) Financing Activities 1.65M USD -4.68%
Net Cash Provided by (Used in) Investing Activities 22.1M USD -80.4%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 212M shares +25.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -32.1M USD -167%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 85.5M USD -8.49%
Deferred Tax Assets, Valuation Allowance 445M USD +11.3%
Deferred Tax Assets, Gross 456M USD +9.14%
Operating Lease, Liability 90.8M USD -4.59%
Depreciation 3.56M USD +1.37%
Payments to Acquire Property, Plant, and Equipment 8K USD -99.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -257M USD +19.3%
Lessee, Operating Lease, Liability, to be Paid 119M USD -7.18%
Property, Plant and Equipment, Gross 149M USD -1.31%
Operating Lease, Liability, Current 7.51M USD +10.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.2M USD +4.25%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.9M USD +3.81%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28.4M USD -14.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13.6M USD +6.19%
Deferred Tax Assets, Operating Loss Carryforwards 244M USD +15.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 22M USD +16.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 14.1M USD +6.19%
Operating Lease, Payments 3.1M USD +3.33%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 13.4M USD -13%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%